Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
May 22, 2024 08:00 ET
|
Assembly Biosciences, Inc.
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at...
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 08, 2024 16:05 ET
|
Assembly Biosciences, Inc.
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
March 28, 2024 16:05 ET
|
Assembly Biosciences, Inc.
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating...
Assembly Biosciences Announces Effective Date of Reverse Stock Split
February 08, 2024 08:00 ET
|
Assembly Biosciences, Inc.
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc....